WaveMan
WaveMan · Company
RVMD · Revolution Medicines, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

RVMD Revolution Medicines (RVMD) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001628171
Quote by TradingView
Form 144 · 19
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
492
13F, latest reported quarter
Conversions, 180 days
19
Codes C/M, not in net · $9.9M priced

What the filings say about RVMD

Insiders, 180 days
-$102.5M net sold
10 sellers · 72% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$84.9M
19 notices

Revolution Medicines insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Revolution Medicines, Inc. insiders sold a net $102.5M of stock across 372 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Sandler Alan B.
Chief Development Officer
SELL
2026-10-01 SECtraded 2026-09-29
2,200
$441.8K
-11.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Sep 16, 2026.
  • The trade is 3.9% of the 56,668 shares held after it.
  • 8 other insiders sold within 30 days.
  • 492 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Development Officer Sandler Alan B. sold about $441.8K of RVMD under a 10b5-1 plan on Sep 29, 2026; 8 other insiders sold within 30 days and 492 funds added in the latest 13F quarter.
Sandler Alan B.
Chief Development Officer
SELL
2026-10-01 SECtraded 2026-09-29
1,609
$324.6K
-11.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Sep 16, 2026.
  • The trade is 2.9% of the 55,059 shares held after it.
  • 8 other insiders sold within 30 days.
  • 492 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Development Officer Sandler Alan B. sold about $324.6K of RVMD under a 10b5-1 plan on Sep 29, 2026; 8 other insiders sold within 30 days and 492 funds added in the latest 13F quarter.
Sandler Alan B.
Chief Development Officer
SELL
2026-10-01 SECtraded 2026-09-29
1,000
$202.8K
-11.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Sep 16, 2026.
  • The trade is 1.8% of the 54,059 shares held after it.
  • 8 other insiders sold within 30 days.
  • 492 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Development Officer Sandler Alan B. sold about $202.8K of RVMD under a 10b5-1 plan on Sep 29, 2026; 8 other insiders sold within 30 days and 492 funds added in the latest 13F quarter.
Sandler Alan B.
Chief Development Officer
SELL
2026-10-01 SECtraded 2026-09-29
1,199
$244.5K
-11.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Sep 16, 2026.
  • The trade is 2.3% of the 52,860 shares held after it.
  • 8 other insiders sold within 30 days.
  • 492 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Development Officer Sandler Alan B. sold about $244.5K of RVMD under a 10b5-1 plan on Sep 29, 2026; 8 other insiders sold within 30 days and 492 funds added in the latest 13F quarter.
Sandler Alan B.
Chief Development Officer
SELL
2026-10-01 SECtraded 2026-09-29
301
$61.6K
-11.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Sep 16, 2026.
  • The trade is 0.6% of the 52,559 shares held after it.
  • 8 other insiders sold within 30 days.
  • 492 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Development Officer Sandler Alan B. sold about $61.6K of RVMD under a 10b5-1 plan on Sep 29, 2026; 8 other insiders sold within 30 days and 492 funds added in the latest 13F quarter.
372 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 367 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$102.5M over 180 days
-$78.0M over 90 days
below 97% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
492 funds bought in last quarter
more than 97% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
6.5% of the float short (float per yahoo 2026-10-26) · 4.7 days to cover · settled 2026-09-30
more than 53% of Pharma & Biotech
What changed in the last 30 days
Oct 1Chief Development Officer Sandler Alan B. sold $1.3M under a 10b5-1 plan (Sep 29)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Sep 29Officer ALAN SANDLER filed to sell $1.3M by Sep 29 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Sep 29SVP & General Counsel Cislini Jeff sold $158.6K under a 10b5-1 plan (Sep 25)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.

Watch RVMD

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+244.1%12M
+0%+105%+209%+314%2025-102025-122026-022026-042026-062026-082026-10 2026-04-15 · GOLDSMITH MARK A sold $18.0M2026-06-15 · Horn Margaret A sold $9.7M2026-08-21 · GOLDSMITH MARK A sold $7.5M2026-08-21 · Cislini Jeff sold $5.4M2026-08-31 · Kim Lorence H. sold $5.3M2026-01-07 · Horn Margaret A sold $5.3M2026-08-21 · GOLDSMITH MARK A sold $5.2M2026-06-17 · Horn Margaret A sold $4.7M2025-11-25 · GOLDSMITH MARK A sold $4.5M2026-09-11 · Kelsey Stephen Michael sold $4.3M2026-09-11 · Kelsey Stephen Michael sold $3.8M2026-09-11 · Kelsey Stephen Michael sold $3.7M2026-08-21 · Cislini Jeff sold $3.6M2026-09-16 · GOLDSMITH MARK A sold $2.7M2026-09-11 · Kelsey Stephen Michael sold $2.7M2026-08-31 · Kim Lorence H. sold $2.6M2026-09-11 · Kelsey Stephen Michael sold $2.4M2026-03-02 · GOLDSMITH MARK A sold $2.2M2026-01-07 · Horn Margaret A sold $2.1M2026-03-25 · Mancini Anthony sold $2.0M2025-11-07 · GOLDSMITH MARK A sold $1.8M2026-06-24 · Anders Jack sold $1.6M2026-06-16 · GOLDSMITH MARK A sold $1.6M2026-08-31 · Kim Lorence H. sold $1.5M2025-11-18 · GOLDSMITH MARK A sold $1.4M2026-08-21 · GOLDSMITH MARK A sold $1.4M2026-08-31 · Kim Lorence H. sold $1.3M2025-11-12 · GOLDSMITH MARK A sold $1.3M2026-03-17 · GOLDSMITH MARK A sold $1.3M2026-09-10 · Mancini Anthony sold $1.2M2025-12-16 · GOLDSMITH MARK A sold $1.2M2026-09-10 · Mancini Anthony sold $1.1M2026-09-16 · Kelsey Stephen Michael sold $1.1M2026-03-25 · Mancini Anthony sold $1.1M2026-08-21 · GOLDSMITH MARK A sold $1.1M2026-09-11 · Kelsey Stephen Michael sold $1.0M2026-09-08 · Kim Lorence H. sold $995.7K2026-01-07 · Anders Jack sold $980.0K2026-09-16 · Horn Margaret A sold $974.8K2026-09-22 · ANDERSON ELIZABETH M sold $959.8K2026-06-24 · Anders Jack sold $956.4K2026-08-21 · Cislini Jeff sold $951.0K2026-09-29 · ALAN SANDLER filed to sell $1.3M2026-09-25 · ANTHONY MANCINI filed to sell $1.9M2026-09-24 · ANTHONY MANCINI filed to sell $112.0K2026-09-22 · Elizabeth Anderson filed to sell $2.9M2026-09-18 · ANTHONY MANCINI filed to sell $347.4K2026-09-15 · Anders Jack filed to sell $802.7K2026-09-15 · Cislini Jeff filed to sell $666.7K2026-09-15 · Goldsmith Mark A filed to sell $2.8M2026-09-15 · Horn Margaret A filed to sell $984.2K2026-09-15 · Kelsey Stephen Michael filed to sell $1.1M2026-09-15 · Mancini Anthony filed to sell $484.4K2026-09-15 · Sandler Alan B filed to sell $67.4K2026-09-11 · STEPHEN KELSEY filed to sell $18.8M2026-09-10 · ANTHONY MANCINI filed to sell $3.2M2026-08-31 · Lorence H Kim filed to sell $15.2M2026-08-21 · JEFFREY TODD CISLINI filed to sell $16.1M2026-08-21 · MARK A GOLDSMITH filed to sell $16.9M2026-08-21 · THE REBECCA GOLDSMITH REVOCABLE TRUST filed to sell $635.2K2026-08-21 · THE JONATHAN GOLDSMITH REVOCABLE TRUST filed to sell $635.2K2026-06-29 · SUSHIL PATEL filed to sell $1.0M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns RVMD: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
13,695,790 sh
$2.6B
FARALLON CAPITAL MANAGEMENT, L.L.C.
13,670,881 sh
$2.5B
FMR LLC
12,200,422 sh
$2.3B
BAKER BROS. ADVISORS LP
11,443,357 sh
$2.1B
Darwin Global Management, Ltd.
10,629,822 sh
$2.0B

Congress trades in RVMD

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

RVMD planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
ALAN SANDLER
Filed 2026-09-29
$1.3M
ANTHONY MANCINI
Filed 2026-09-25
$1.9M
ANTHONY MANCINI
Filed 2026-09-24
$112.0K
Elizabeth Anderson
Filed 2026-09-22
$2.9M
ANTHONY MANCINI
Filed 2026-09-18
$347.4K

RVMD mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Tema Oncology ETF
$13.6M position · as of 2026-05-31
7.7%
VanEck Biotech ETF
$20.9M position · as of 2026-06-30
5.3%
Invesco Dorsey Wright Healthcare Momentum ETF
$11.6M position · as of 2026-07-31
4.9%
iShares Genomics Immunology and Healthcare ETF
$8.7M position · as of 2026-07-31
4.6%
Marsico Midcap Growth Focus Fund
$41.1M position · as of 2026-06-30
4.4%
NICHOLAS PARTNERS SMALL CAP GROWTH FUND
$7.1M position · as of 2026-06-30
3.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
19 registered trials, 15 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
4
Phase 1
3 active
1
Phase 2
0 active
7
Phase 3
7 active
1
Not applicable
0 active
6
Multi-phase
5 active
What changed recently
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
2026-09-23 · Completion moved 2027-05-15 → 2028-09-30
PHASE1,PHASE2
Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pan
2026-09-02 · Available → Approved For Marketing
,
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Dr. Goldsmith
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$14.7M
$37.1M
$4.5M
+101%
+25%
2024
$10.1M
$20.3M
$4.3M
+10%
+17%
2023
$10.4M
$14.0M
$3.8M
-28%
+14%
2022
$7.2M
$8.6M
$2.5M
-40%
+10%
2021
$7.8M
-$3.5M
$2.4M
-36%
+25%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $102.5M sold by insiders over 180 days, 492 funds added last quarter, $84.9M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

RVMD financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2024-01-01 to 2024-12-31
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$1.2B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-79.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-52.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-52.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-3.1%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$0$0$11.6M$35.4M
Operating income-$1.2B-$689.5M-$487.2M-$258.3M
Net income-$1.1B-$600.0M-$436.0M-$249.0M
EPS (diluted)-5.95-3.58-3.86-3.08
Operating cash flow-$897.7M-$557.4M-$350.6M-$224.4M
Cash$383.7M$543.1M$696.1M$161.4M
SEC XBRL, fiscal years, as known on 2026-10-28

RVMD Stock Sonar score 4/7 axes

Find similar shapesCompare

RVMD ranks highest on institutional and government (97th percentile) and risk and compliance (50th), and lowest on insider conviction (4th), among Pharma & Biotech peers.

Profitability
43
Inputs
  • Return on equity-79.1% · 39 pct, sector of 545
  • Return on assets-52.4% · 43 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-52.4% · 48 pct, sector of 576
Insider conviction
4
Inputs
  • Net Form 4 buying (codes P and S), 180d-$24.5M · 8 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
97
Inputs
  • Funds adding, latest quarter492 · 97 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
50
Inputs
  • Short interest, % of float+6.5% · 52 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+10.8% · 49 pct, sector of 511
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

RVMD filings, in plain words

Are Revolution Medicines insiders buying or selling RVMD?

In the 180 days to 2026-10-28, Revolution Medicines insiders were net sellers, a net $102.5M across purchases and sales reported on Form 4, by 10 sellers.

Are there planned insider sales of RVMD?

Yes. 19 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $84.9M of stock; the latest, by ALAN SANDLER, was filed 2026-09-29.

Read the full summary

In the 180 days to 2026-10-28, Revolution Medicines insiders were net sellers of RVMD, a net $102.5M across purchases and sales reported on Form 4 by 10 sellers. 72% of the 109 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 19 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $84.9M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies